SWP
ATXS

Stratos Wealth Partners’s Astria Therapeutics ATXS Stock Holding History

Stratos Wealth Partners’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-42,188
Closed -$315K – 1375
2023
Q3 		$315K Sell
42,188
-20,425
-33% -$174K 0.01% 998
2023
Q2 		$522K Buy
+62,613
New +$722K 0.01% 748

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Stratos Wealth Partners's ATXS Position: Q4 2023 in Review

Stratos Wealth Partners sold out of Astria Therapeutics (ATXS) in Q4 2023, closing a stake of 42,188 shares — an estimated $315K sold.

Stratos Wealth Partners first reported a position in ATXS in Q2 2023 and held it in 2 quarters. The position peaked at $522K in Q2 2023. 80 funds tracked by Wall St. Rank hold ATXS as of Q4 2023.

  • Stratos Wealth Partners reported no remaining Astria Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Stratos Wealth Partners sold 42,188 Astria Therapeutics shares in Q4 2023, an estimated $315K.
  • Stratos Wealth Partners first reported a position in Astria Therapeutics in Q2 2023 and held it in 2 quarters.
  • Stratos Wealth Partners's Astria Therapeutics position peaked at $522K in Q2 2023.
  • 80 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2023.

Based on Stratos Wealth Partners's 13F filing for Q4 2023, filed 24 Jan 2024.